Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
Updated Data from Ph 1b/2 Study of Muzastotug + KEYTRUDA in Late-line Patients with MSS CRC Demonstrate Improved Durability of Response April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Imfinzi + Imjudo combined with lenvatinib and TACE demonstrated a statistically significant PFS improvement in embolisation-eligible unresectable liver cancer in EMERALD-3 Ph 3 trial April 7, 2026
Type C FDA Meeting Announced to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer April 7, 2026
FDA Accepts Priority Review of NDA for Lirafugratinib as 2L Cholangiocarcinoma Treatment April 7, 2026
Namodenoson Positive Data in Ph 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Announced March 31, 2026
Positive Topline Results from Ph 2 PANOVA-4 Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer Announced March 31, 2026
Israeli Ministry of Health approves initiation of Ph 2/3 trial of SIL204 for the treatment of locally advanced pancreatic cancer March 31, 2026
FDA Accepts NDA Resubmission for Rivoceranib in Combination with Camrelizumab for 1L HCC March 31, 2026
FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer Concluded March 24, 2026
Mature median OS data from ongoing ACCENT clinical trial of narmafotinib + chemo in advanced pancreatic cancer announced March 24, 2026
Positive Ph 1 expansion data for EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC announced March 24, 2026
Positive End-of-Phase 2 Meeting with FDA Regarding the Design of a Ph 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma Announced March 24, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
